Pseudoachondroplasia (PSACH) is an autosomal-dominant osteochondrodysplasia due to mutations in the gene encoding cartilage oligomeric matrix protein (COMP). Clinical diagnosis of PSACH is based primarily on family history, physical examination, and radiographic evaluation, and is sometimes extremely difficult, particularly in adult patients. Genetic diagnosis based on DNA sequencing, on the other hand, can be expensive, time-consuming, and intensive because COMP mutations may be scattered throughout the gene. However, there is evidence that decreased plasma COMP concentration may serve as a diagnostic marker in PSACH, particularly in adult patients. Here, we report the serum and/or plasma COMP concentration-based differential diagnosis of a family with affected adult members. The mean serum and/or plasma COMP concentrations of the three affected family members alive (0.6970.15 and/or 0.8170.08 lg/ml, respectively) were significantly lower than those of an age-compatible control group of 21 adults (1.5270.37 and/or 1.3770.36 lg/ml, respectively; Po0.0001). Bidirectional fluorescent DNA sequencing-based genetic diagnosis of these patients revealed a heterozygous mutation for the nucleotide change 1532A4G in exon 14 of the COMP gene, resulting in a substitution of amino acid 511 from aspartic acid to glycine in COMP. Thus, serum and/or plasma COMP concentration may be suggested as an additional diagnostic marker to aid clinical and radiographic findings in suspected cases of PSACH.
Introduction
Pseudoachondroplasia (PSACH; MIM 177170) is an autosomal-dominant osteochondrodysplasia affecting at least 1 in 20 000 individuals and is characterized by disproportionate short stature, deformity of the lower limbs, short fingers, loose joints, and ligamentous laxity. 1 -3 Other characteristic features include normal craniofacial appearance and early-onset osteoarthritis. Its radiological findings include small, irregular epiphyses and irregular, mush-roomed metaphyses of all tubular bones and flattening and/or anterior beaking of vertebrae. Adult stature has been reported as 82 -130 cm. Although the vertebral changes resolve with age (ie, after puberty, the vertebrae become more normal in appearance), the epiphyseal changes of the long bones become more severe, leading to progressive degeneration and severe osteoarthritis. PSACH is caused exclusively by mutations in the cartilage oligomeric matrix protein (COMP) gene located on chromosome 19p13.1, and, to date, all cases of PSACH have been ascribed to mutations in exons 8 -19 of this gene. 4 COMP is a homopentameric glycoprotein found in cartilage, tendon, ligament, smooth muscle, synovium, and osteoblast. 5, 6 COMP is described as a key component of the extracellular matrix (ECM) of the skeleton. COMP binds collagen types I, II, and IX through its C-terminal globular domain, 7 -9 forming a large structural network of macromolecules in the ECM. The secretion of mutant COMP from chondrocytes is markedly delayed, presumably due to a prolonged association with chaperones in the rough endoplasmic reticulum (rER). 10 Thus, PSACH appears to be an rER storage disease most likely caused by improper folding of mutant COMP. The growth failure of patients with PSACH may be explained by an increased cell death of growth plate chondrocytes. Current clinical diagnosis of PSACH is based primarily on family history, physical examination, and radiographic evaluation. However, clinical presentation varies substantially between individual cases and depends on the patients' age. Most radiographic changes are not disease-specific, leading to misdiagnosis, particularly in adult patients. 11 It has been reported that the characteristic findings of the spine resolves with time and normalizes in adolescence, making diagnosis even more difficult. 12 In addition, radiological diagnosis is more difficult in adulthood owing to associated changes resulting from osteoarthritis. 11 Genetic diagnosis based on DNA sequencing, on the other hand, can be expensive and labor-intensive because COMP mutations can be scattered throughout the gene containing 19 exons. 4 However, there is evidence that decreased plasma COMP concentration may serve as a diagnostic marker in PSACH, particularly in adult patients. 12 Mabuchi et al 12 presented
evidence that circulating COMP is decreased in PSACH patients carrying COMP mutations compared with controls. Here, we report the serum and/or plasma COMP concentration-based differential diagnosis of a family with affected adult members in two generations. All the three affected members alive were adults with noncharacteristic radiological and clinical features.
Materials and methods

Case history
The subjects are the three dwarf members (individuals II-4, II-6, and III-1) of a family (see pedigree in Figure 1 ). The grandparents of the proband (individual III-1) were first cousins to each other. They have had five daughters, of whom four of them were affected, and two healthy sons. Two of the four affected daughters (individuals II-2 and II-3) died at ages 78 and 45, respectively. Individual II-4 is one of the two affected daughters alive. She is 80 years old, 100 cm in height, and suffers from severe osteoarthrosis. Individual II-6, the other affected-daughter alive, on the other hand, is 60 years old, 90 cm in height, and the mother of the proband. She also suffers from severe osteoarthrosis. The proband, 36 years old and 119 cm in height, is the only daughter of individual II-6 from a possibly consanguineous marriage to individual II-5. She is an intelligent woman with normal craniofacial appearance. A short stature, disproportionately short limbs, and short fingers are her only known medical problems ( Figure 2 ). Her radiological skeletal survey showed shortening of long bones and widening in her epiphyses ( Figure 3 ). Phalanges, metacarpals, and metatarsals were short and thick with cone-shaped epiphyses (Figure 3a These adulthood findings were uncharacteristic of a given osteochondrodysplasia, but were suggestive of PSACH or Acromesomelic dysplasia, Maroteaux type (AMDM, MIM 602875). The review of this family by the European Skeletal Dysplasia Network (ESDN) supported our diagnosis (Case number ESDN-00490) and suggested COMP mutation analysis as the first choice of action for the definitive diagnosis. Serum/plasma COMP levels in PSACH AC Tufan et al Serum and/or plasma COMP assay All women participating in this study as the control group were selected at random (ie, in terms of any given health condition) from the polyclinics of Pamukkale University Hospital and gave informed written consent before blood sampling. Selected participants of the control group were matched to the age range of three patients analyzed for COMP mutations in this study. Three milliliters of peripheral blood were collected into an EDTA-containing tube for plasma separation, and 5 ml of peripheral blood was collected into a plain tube containing no anticoagulant for serum separation. The blood samples were centrifuged at 3000 g for 10 min, and the plasma and serum were carefully removed from their respective tubes and transferred into plain polypropylene tubes. The samples were stored at À801C until further processing. Serum and/or plasma COMP concentrations of 3 patients and 21 controls were analyzed on the basis of an enzyme immunoassay kit (Wieslab, Lund, Sweden), according to the manufacturer's protocol and as described elsewhere. 12 DNA extraction and COMP mutation detection Genomic DNA was extracted from blood samples of all three affected individuals, that is, II-4, II-6, and III-1, using standard methods. Bidirectional fluorescent DNA sequencing was employed to identify mutations in exons 8 -19 of the COMP gene.
Statistical analysis
Statistical analysis for serum and/or plasma COMP concentrations were performed using the nonparametric Mann -Whitney's U-test, and Po0.05 was taken as statistically significant.
Results
Serum and/or plasma COMP concentrations
The mean serum and/or plasma COMP concentrations of three affected family members alive (0.6970.15 and/or 0.8170.08 mg/ml, respectively) were significantly lower than those of an age-compatible control group of 21 adults (1.5270.37 and/or 1.3770.36 mg/ml, respectively; Po0.0001; Table 1 ). There was no overlap in the distribution of serum and/or plasma COMP concentration between PSACH patients and controls (Figure 4 ).
COMP mutation detection
All three affected family members were heterozygous for the nucleotide change c.1532A4G in exon 14 of the COMP gene ( Figure 5 ; nucleotide numbering is according to cDNA sequence with Genbank accession number XM_009336. Nucleotide 1 has been counted as the first nucleotide of the translation initiation codon). This sequence change is predicted to result in a substitution of amino acid 511 from aspartic acid to glycine in COMP (p.Asp511Gly).
Discussion
Accurate diagnosis of a given osteochondrodysplasia is a time-consuming and often complicated process, involving the clinical and radiographic evaluation of the proband and other family members. Generally, the clinical and radiographic evaluations are used to determine a differential diagnosis before a confirmatory molecular test. This Serum/plasma COMP levels in PSACH AC Tufan et al study aimed to test the value of serum and/or plasma COMP concentration as a possible diagnostic marker in differentiating PSACH from other osteochondrodysplasias before a more expensive and labor-intensive confirmatory molecular test.
The skeletal survey of the proband revealed a shortlimbed dwarfism with acromesomelic predominance, a generalized epiphyseal and metaphyseal involvement, and uncertain vertebral changes. These radiological findings alone did not allow a clear differentiation between AMDM and PSACH, which were thought to be the most likely diagnoses. The suspected clinical diagnosis of PSACH in the family was supported by decreased serum and/or plasma COMP concentration, and, then subsequently, confirmed by DNA sequencing of COMP and the identification of a potential disease-causing mutation.
The heterozygous nucleotide change (c.1532A4G) in exon 14 of the COMP gene, which is predicted to result in a substitution of amino acid 511 from aspartic acid to glycine has not been published previously. However, it is likely to be the cause of proband's PSACH since aspartic acid 511 is a conserved amino acid in the final repeat of the Ca 2 þ -binding TSP-3 (calmodulin-like) repeat region of COMP. 4 Furthermore, a mutation of aspartic acid 511 to histidine has been reported to be pathogenic in an unrelated patient with PSACH. 13 Testing of the affected Figure 3 Radiological skeletal survey of the proband showing shortening of long bones and widening in her epiphyses. The hands and feet were small. Phalanges, metacarpals, and metatarsals were short and thick with cone-shaped epiphyses (a and d). The tibiae and fibulae were mildly shortened with splayed metaphyses and epiphyses (d). The shortness of the radii and ulnae was more prominent with widened epiphyses, and mild bowing was present in proximal radii (data not shown). Chest radiogram showed superiorly curved clavicles and spatulate ribs with marked costochondral calcifications (c). Lateral radiograph of the spine revealed straightening of dorsal kyphosis with decreased anteroposterior diameter of the chest, and small central endplate depressions of some dorsal vertebrae (b). There was normal widening of the interpedicular distances from upper to lower spine (b). Pelvis radiogram showed flattened, irregular, and fragmented femoral heads with shortened necks, increased acetabular angles, and widened symphysis pubis (e). mother and maternal aunt of the proband, both of whom also tested heterozygous-positive for the nucleotide change 1532A4G, is further evidence that this sequence change is likely to be the cause of the proband's PSACH. On the other hand, the pedigree of this family (Figure 1 ) is very interesting since the proband's grandparents were apparently phenotypically normal. Thus, one would have to postulate significant germline mosaicism for them to have 4 of 7 children affected with an autosomal-dominant disorder.
The diagnosis of PSACH, using DNA sequencing of COMP, is not always easy to accomplish as the mutations can be scattered throughout 12 exons of COMP (exons 8 -19 COMP concentration of the same patients as 0.8170.08 mg/ml (range: 0.73 -0.88). All these detected decreases were statistically significant (Po0.0001). In addition, Mabuchi et al 12 reported that the same approach also reveals significant decrease in plasma COMP levels of multiple epiphyseal dysplasia patients carrying COMP mutations.
In conclusion, serum and/or plasma COMP concentration analysis may be suggested as a time and cost-efficient additional diagnostic marker to clinical and radiographic findings in osteochondrodysplasias caused by mutations in the COMP gene.
